A new PET scan probe for imaging kidney tumors
Tests 18F-N230A PET/CT imaging in adults with suspected or confirmed kidney tumors.
Plain-language title generated from the registry record
Registry title: 18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07875959
- Record updated
- 15 October 2026
- Original description
Renal cell carcinoma and renal pelvic urothelial carcinoma are common malignant tumors of the urinary system. Accurate preoperative differentiation between these tumor types is important for treatment planning, while conventional imaging methods may have limitations in characterizing tumor biology.Read full original descriptionShow less
A Study to Evaluate 18F-N230A PET/CT Imaging of Nectin-4 Expression in Patients With Renal Cell Carcinoma and Renal Pelvic Urothelial Carcinoma
Renal cell carcinoma and renal pelvic urothelial carcinoma are common malignant tumors of the urinary system. Accurate preoperative differentiation between these tumor types is important for treatment planning, while conventional imaging methods may have limitations in characterizing tumor biology.
Nectin-4 is a tumor-associated molecular target that is highly expressed in several epithelial malignancies, particularly urothelial carcinoma. 18F-N230A is a novel PET imaging probe targeting Nectin-4. This study aims to evaluate the safety, biodistribution, and imaging characteristics of 18F-N230A PET/CT in patients with suspected or confirmed renal tumors.
Participants enrolled in this study will undergo 18F-N230A PET/CT imaging and 18F-FDG PET/CT imaging. The imaging findings and quantitative parameters will be analyzed and compared. Pathological results obtained from surgery or biopsy will be used as the reference standard to evaluate the potential value of 18F-N230A PET/CT in differentiating renal cell carcinoma from renal pelvic urothelial carcinoma.
This study may provide a new molecular imaging approach for improving the preoperative diagnosis of renal tumors and supporting individualized clinical decision-making.
Inclusion: Participants aged ≥18 years; Patients with suspected or confirmed renal tumors who are scheduled for pathological examination by biopsy or surgical resection within 2 months; Patients who can understand the study procedures and voluntarily provide written informed consent; Patients who can cooperate with PET/CT imaging procedures.
Exclusion: Patients with a history of other malignant tumors; Patients with severe abnormalities in liver function, renal function, or blood cell counts; Patients unable to understand the study procedures or unable to cooperate with imaging examinations; Patients considered unsuitable for participation by the investigator.